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Abstract 
The DUSP26 gene encodes for an atypical dual 
specificity phosphatase commonly referred to as 
Dusp26 or MPK8. Although its physiological role is 
poorly understood, different substrates have been 
reported to be dephosphorylated by Dusp26, 
including p53, Kif3, Erk and p38. In this report we 
summarize the current knowledge on DUSP26 gene, 
its transcripts, the encoded protein and its function in 
normal and tumorous tissues. Notably, the 
phosphatase is overexpressed in neuroblastoma and 
ATC cells, where it promotes chemoresistance by 
inhibiting the p53 and the p38 proteins,  
respectively. Dusp26 represents a promising novel 
therapeutic target to be integrated with others and 
with conventional medicine, to improve survival 
outcome in patients and to reduce toxicity. 
Keywords 
DUSP26, dual-specificity phosphatase, MKP, 
phosphopeptides, MAPK 
Identity 
Other names: MKP-8, LDP-4, NEAP, SKRP3, 
DUSP24, NATA1 
HGNC (Hugo): DUSP26 
Location: See Figure 1. 
Figure 1: Chromosomal location of human DUSP26 gene, according to NCBI. DUSP26 gene is located on Chr 8, starting at 
33600028 and ending at 33591330. The gene orientation is on the minus strand. 
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Figure 2: Human DUSP26 gene is located on chromosome 8. According to Ensemble (release of april 2015) the longest 
transcript is 1835 bases long and it consists of four exons (represented as boxes) and 3 introns (represented as lines). Two 
shorter isoforms have been reported, 1373 and 729 nucleotides long, respectively. 
 
DNA/RNA 
Description 
The human DUSP26 gene is located on chromosome 
8p12, starting at 33600028 and ending at 33591330 
and comprises 4 exons (NCBI, 2015) 
Transcription 
According to Ensemble, three splicing variants have 
been reported for Dusp26 transcripts. The longest 
isoform comprises four exons and is considered the 
canonical sequence.  
The second isoform also comprises four exons, and 
gives rise to a protein of the same length (211 aa), 
however it has shorter regulative sequences both at 
3' and 5'. The third variant instead, consists of two 
exons and transcribes for a shorter protein, lacking 
70 aminoacids at the C-terminus. In uniprot database 
this third variant is annotated in a different entry 
(E5RHD0), while a shorter isoform lacking the first 
125 aminoacids is reported, which is not considered 
in ensemble. 
Pseudogene 
None 
 
Figure 3: A) Schematic cartoon representing Dusp26 protein. The central Dusp26 phosphatase domain (residues 61-186), is 
surrounded by two N-terminal alpha-helices (helix alpha 1 and helix alpha 2) and a C-terminal helix (helix alpha 9) (Lokareddy et 
al, 2013). B) Ribbon depiction of the three dimensional structure of the catalytic domain of Dusp26 (aa 60-211) (adapted from 
PDB entry 4B04, (Won et al, 2013)) 
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Figure 4: Graphical representation of Dusp26 interactors and substrates. Brown edges indicates phosphatase activity on the 
linked proteins, while blu edges link Dusp26 to scaffolding interactors. Dusp26 is a dual specificity phosphatase, and its 
molecular function is to dephosphorylate pS/pT or pY residues on the surface of its substrates. However, the physiological role of 
Dusp26 is still not completely elucidated, and it may be tissue-dependent (Patterson et al, 2010). Knockdown mice do not show 
severe malformations, presumably due to redundancy within the DSP family, but failure to thrive was reported, associated with 
decreased body weight, decreased circulating LDL, proteins and magnesium levels (http://www.mousephenotype.org/). In 
cultured PC12 cells (an adrenal-gland derived cell line that can differentiate into neuron-like cells) Dusp26 overexpression was 
shown to impair NGF-induced neuronal differentiation and to suppress neurite outgrowth (Wang et al, 2006). This is relevant 
when considering that Dusp26 was shown to be overexpressed in many human neuroblastoma cell lines and in primary tissue 
samples (Shang et al, 2010). However, in MCF10A epithelial cells the overexpression of the phosphatase resulted in reduced 
colony formation (Patterson et al, 2010) 
 
Protein 
Description 
Dusp26 protein consists of 211 aminoacids with a 
predicted molecular mass of 23.945 kDa.  
The phosphatase is an 'atypical DUSP' able to 
dephoshorylate both phosphotyrosine and 
phosphothreonine/phosphoserine residues, thanks to 
the 126 aminoacids DSP catalytic domain 
(Vasudevan et al, 2005).  
This domain consists of five beta -sheets sandwiched 
between six alpha -helices (alpha 3-8), with a 
shallow catalytic site pocket. As shown in the 
diagram, the catalytic domain is surrounded by two 
N-terminal alpha -helices (alpha 1 and alpha 2) and 
one C-terminal helix (alpha 9) (Lokareddy et al, 
2013).  
The central core contains a PTP signature motif with 
the consensus Cys-(X)5-Arg-(Ser/Thr) conserved 
among the PTP class I members, where Cys152 and 
Arg158 form, together with Asp120, the catalytic 
triad.  
The catalytic residue Cys152 which primes the 
reaction, is buried 7 ÅA below the enzyme surface, 
at the bottom of the catalytic site pocket (Lokareddy 
et al, 2013; Won, et al., 2013).  
Dusp26 also presents an "AYLM" motif that is 
typical of MKPs, but lacks the CDC25 homology 
domain (Patterson et al, 2009; Vasudevan et al, 
2005). 
Expression 
Dusp26 is expressed in the brain, heart, skeletal 
muscle, adrenal gland and spinal cord (Hu and 
Mivechi, 2006; Takagaki et al, 2007; Vasudevan et 
al, 2005; Wang et al, 2006). It is also expressed at 
lower levels in the testis and thyroid gland (Wang et 
al, 2006) 
Localisation 
Dusp26 localizes to the nucleus and the cytoplasm 
(Takagaki et al, 2007; Vasudevan et al, 2005; Wang 
et al, 2006) 
Function 
At the molecular level, several Dusp26 substrates 
have been reported and we will briefly summarize 
them. Dusp26 was reported to dephosphorylate 
MAPKs such as p38, Erk and JNK, as well as Akt 
kinase,and to regulate their activity (Hu and 
Mivechi, 2006; Vasudevan et al, 2005; Wang et al, 
2006; Wang et al, 2008; Yu et al, 2007). However, 
other authors have reported no effect of Dusp26 on 
MAPK, which suggests that this activity might not 
be the major function of the phosphatase, or that it 
might behave differently in different cell types 
(Patterson et al, 2010). Notably Hsf4b and Scrib 
have been proposed as regulators to bridge the 
protein with MAPK substrates (Hu and Mivechi, 
2006; Sacco et al, 2014). A similar role was proposed 
for the Adenylate Kinase (AK2), which was shown 
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to form a complex with Dusp26 and to stimulate its 
phosphatase activity toward Fas-associated protein 
with death domain (FADD),although the molecular 
mechanism of this activation is unknown (Kim et al, 
2014).  
However, the authors specify that this complex does 
not modulate apoptosis and that Fadd 
phosphorylation level is irrelevant to cell death, 
while it is involved in the control of cell 
proliferation.  
The Kif3a subunit of the KIF3 protein-motor 
complex might be another scaffold subunit that leads 
the phosphatase to act on Kap3(Tanuma et al, 2009).  
It is not unfrequent that the catalityc activity of 
enzymes is increased upon binding to interactors that 
function as coactivators, and the organization of 
complexes could be a refined mechanism to control 
the specificity.  
Notably, the structural comparison of Dusp26 with 
other Dusps reveals two gaps nearby the catalytic 
domain which could be targeted for the binding of 
physiological interactors or allosteric regulators 
(Won et al, 2013).  
Dusp26 was also reported to directly bind and 
dephosphorylate Ser20 and Ser37 of the tumour 
suppressor p53, both in vitro and in vivo (Shang et 
al, 2010). 
As a result of its function as MAPKs, KIF3 and p53 
regulator, modulation of its activity and/or its 
expression has been proposed, as well as that of other 
atypical Dusps, as a promising anti-cancer therapy 
(Nunes-Xavier et al, 2011; Song et al, 2009).  
The challenge for the future infact, is to complement 
various therapeutical targets, to treat patients with 
specific and more effective therapies. A current 
priority is the elucidation of the molecular basis for 
the insorgece of acquired drug resistance during 
therapy, and for the selection of apoptosis-resistant 
cells.  
Although more than 50% of all human cancers have 
p53 deletion or mutation, neuroblastoma (NB) is 
known to maintain functional p53, but to defect in 
apoptotic pathways.  
It was shown that Dusp26 has an important role in 
the chemoresistance of NB cancer cells, and inhibits 
doxorubicin- and genotoxic-stress-induced 
apoptosis by dephosphorylation and inactivation of 
p53.  
In Dusp26 knockdown cells there is a significant 
enhancement of apoptosis and a concomitant 
iperphosphorylation of p53, while the 
overexpression of the phosphatase promotes cell  
resistance (Shang et al, 2010). Althought Dusp26 is  
 
overexpressed in neuroblastoma cells, as described  
below, no specific drug has been developed yet to 
selectively target Dusp26 (Song et al, 2009). 
However it is reasonable to think that interfering 
Dusp26 dephosphorylation of p53 would promote 
NB cells apoptosis and help chemosensitivity (Shang 
et al, 2010).  
Similarly, in anaplastic tyroid cancer cells (ATC), 
the phosphatase downregulates apoptosis by 
inhibiting p38 MAPK (Yu et al, 2007).  
In PC12 cells, however, low levels of the 
phosphatase are required for differentation, while 
Dusp26 overexpression down-regulates the 
PI3K/Akt pathway.  
In these conditions, NGF-induced phosphorylation 
of mTOR on Ser2448, the Akt specific targeted 
serine, is decreased, and PC12 cells are more 
sensible to cisplatin-induced apoptotic stimuli 
(Wang et al, 2006). 
Beyond regulating cell differentiation and apoptosis 
in these cell systems, Dusp26 was also hypothesized 
to control cell transformation in other human 
malignancies, by exerting a tumour-suppressor 
activity enhancing cell-cell adhesion. 
Dephosphorylation of the Kap3 subunit of the KIF3 
microtubule-dependent protein motor infact, results, 
by unknown mechanism, to N-cadherin/beta-catenin 
colocalization in membrane ruffles and in sites of 
cell contacts (Tanuma et al, 2009). 
These findings suggest that the final effect of the 
phosphatase depends on tissue-specific substrates 
and a fine characterization of its fuctional role in 
different cancer cells is necessary to develop 
selective therapies.  
While the catalytic core of the atypical Dusps is well 
conserved among the members of the family, the 
binding of ligands to more specific N and C terminal 
regions (Sacco et al, 2014) allows for the design of 
selective inhibitors. 
Homology 
Dusp26 is a member of the dual specificity family of 
protein phosphatases.  
It shares the highest homology with Dusp13, Dusp 
27 and Dusp3/VHR protein phosphatases (Patterson 
et al, 2009; Pavic et al, 2015; Takagaki et al, 2007; 
Vasudevan et al, 2005; Won et al, 2013). 
The human Dusp26 protein is highly conserved 
within Mammalia, and shows 100%, 98%, 97% and 
94% of identity with chimpanzee, rat, mouse and pig 
orthologs, respectively (percentages according to 
Blast bl2seq).  
Dusp26 also shows high similarity with chicken, 
chamaleon, western clawed frog, Japanese ricefish 
and zebrafish homologous proteins. 
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Figure 5: Missense mutation of Dusp26 (reported in Cosmic database). 41 missense mutation are reported in Cosmic. Two 
different missense substitutions were found in position 441 of the cDNA (441G>C; 441G>T) both leading to the mutation of the 
Lysine 147 in to an Asparagine. Substitution of Cysteine 152 to Serine instead is described elsewhere. 
 
Mutations 
Somatic 
Several point mutations of Dusp26 coding region are 
reported in Cosmic database (Forbes et al, 2015). 
The analysis of 19779 samples led to the 
identification of 41 missense mutations, 16 
synonymous and 2 nonsense mutations (Forbes et al, 
2015) (april 2015 release).  
None of them are associated with a specific 
phenotype. 
The mutation C152S instead, inactivates the 
phosphatase function of the protein (Vasudevan et al, 
2005; Wang et al, 2006). 
Amplification of genomic copy number of DUSP26 
gene, overexpression of its transcript, as well as 
downregulation, have all been reported to be related 
to human cancers (see also below).  
Actually, the amplification of the genomic copy 
number of DUSP26 was reported in Anaplastic 
Thyroid Cancer cells, and the consequential 
overexpression of the transcript was determined by 
RT-PCR (Yu et al, 2007).  
Overexpression of DUSP26 was determined at RNA 
and protein level in neuroblastoma cell lines and in 
primary tumour samples(Shang et al, 2010). 
Downregulation of Dusp26 RNA was also observed 
in ovarian cancer, medulloblastoma and 
glioblastoma cell lines (Patterson et al, 2010) 
Implicated in 
Anaplastic Thyroid Cancer (ATC) 
Note 
The amplification of 8p11-12 region (containing the 
DUSP26 gene) has been observed in many types of 
cancer: breast, bladder, lung and ovarian cancer; 
however no target gene has been identified in those 
cases. 
In Anaplastic Thyroid cancer instead, the 
overexpression of DUSP26 mRNA was confirmed in 
(Yu et al, 2007), and its oncogenic activity was 
dependent on its phosphatase activity on p38. 
Disease 
Thyroid carcinomas are classified in medullary, 
papillary, follicular and anaplastic. This last form is 
relatively rare, constituting to less than 2% of all 
thyroid cancers, but shows extremely aggressive 
behaviour and few effective treatment options, 
resulting in high mortality rates (Schiff et al, 2004). 
Prognosis 
Patients with ATC have a grave prognosis, with a 
mortality rate of almost 100% and a mean survival 
of few months (Schiff et al, 2004) 
Neuroblastoma (NB) 
Note 
DUSP26 was overexpressed in some (but not all) 
neuroblastoma cell lines and in retinoblastoma and 
neuroepithelioma cell lines (Patterson et al, 2010; 
Shang et al, 2010; Vasudevan et al, 2005). 
Immunohistochemistry showed high DUSP26 
expression in high-risk neuroblastoma samples 
compared with low risk groups (Shang et al, 2010). 
The phosphatase was shown to contribute to the 
resistance of neuroblastoma cells to doxorubicin-
induced apoptosis, by dephosphorylating the tumour 
suppressor p53 (Shang et al, 2010). 
Disease 
Neuroblastoma is a tumour of the sympathetic 
nervous system and is the most common solid 
tumour in children (Brodeur et al, 2014). NB cells 
can be hyperdiploid or near triploid, with 
chromosomal aberration, rearrangements and gene 
amplifcations (Brodeur, et al., 2014). Several genes 
have been reported to be activated in NB: MYCN, 
ODC1, ALK, TRK, PTPN11 (Brodeur, et al, 2014) 
and DUSP26 (Shang et al, 2010) 
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Prognosis 
The clinical behaviour of this disease is highly 
heterogeneous, and spans from spontaneous 
regression, frequent in children under 18 months of 
age, to metastatic tumours with 40-50% survival rate 
(Brodeur and Bagatell, 2014). 
Glioblastoma (GBM) 
Note 
Different forms of GBM display distinct molecular 
abnormalities, as reviewed in (Veliz et al, 2015) . 
Gene amplifications, deletions and/or 
overexpression have been reported, and, among 
them, loss of the dual specificity phosphatase PTEN 
is a very common feature (Veliz et al, 2015). Dusp26 
mRNA expression is also downregulated in human 
glioblastoma cell lines and in primary tumour 
samples and its downregulation was associated with 
invasive phenotypes (Patterson et al, 2010; 
Prabhakar et al, 2014; Tanuma et al, 2009; 
Vasudevan et al, 2005).It has been proposed that 
Dusp26 enhances cell-cell adhesion in GBM by 
promoting N-cadherin/Beta-catenin localization at 
the plasma membrane (Tanuma et al, 2009).  
The downregulation of Dusp26 mRNA has been 
observed also in ovarian cancer and 
medulloblastoma cell lines (Patterson et al, 2010) 
Disease 
Glioblastoma Multiforme (GBM)is a genetically 
heterogeneous group of brain tumours, which 
originates from glial cells (Urbanska et al, 2014). 
The 90% of GBM cases are primary tumours, 
developed from normal cells by multistep 
tumorigenesis, while 10% are secondary tumours 
developed from astrocytomas (Urbanska et al, 2014). 
The two types of tumours show no morphological 
differences, both presenting small cells with 
increased nuclear to cytoplasmic ratios, however 
secondary tumours grow slower and have a better 
prognosis (Urbanska et al, 2014). 
Prognosis 
Although metastases have been rarely reported in 
GBM, primary tumours are very aggressive, with 
overblown vascularization and resistance to 
conventional radiotherapy and chemotherapy, and 
with a 5-year survival rate of 5% (Veliz et al, 2015). 
To be noted 
This work was supported by Italian Ministry of 
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